New hope for tough liver cancers: testing a powerful Three-Pronged attack
NCT ID NCT07466225
Summary
This study aims to see if adding a targeted liver chemotherapy infusion (HAIC) to a standard two-drug regimen (lenvatinib and a PD-1 inhibitor) works better for people with advanced liver cancer that has grown into major blood vessels or bile ducts. It will enroll 150 patients who have not yet started treatment and compare the two approaches. The main goal is to see if the triple therapy helps patients live longer and controls the cancer better, while carefully tracking side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University Cancer Hospital
Beijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.